How to Buy Beone Medicines Stock
Beone Medicines Ltd
BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies.
Beone Medicines stock last closed at $275.69, up 0.35% from the previous day, and has increased 8.88% in one year. It has overperformed other stocks in the Biotechnology industry by 0.48 percentage points. Beone Medicines stock is currently +40.34% from its 52-week low of $196.45, and -28.43% from its 52-week high of $385.22.
There are currently 1.44B shares of ONC outstanding. The market cap of ONC is $30.62B. In the past 24 hours, 209,000 ONC shares were traded.
How to Buy Beone Medicines Stock
Not sure how to invest in Beone Medicines stock? Here's how.
- Choose where to buy Beone Medicines stock: You need to pick a stock brokerage, but don't worry - we've tried dozens of online stock brokerages and apps to help you decide where to buy Beone Medicines stock.
- Create your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
- Put funds into your investment account: Select your method of payment and add your details.
- Evaluate Beone Medicines stock: The Beone Medicines ticker symbol is ONC. Is Beone Medicines stock a good investment? Should you buy shares of ONC? How do ONC's underlying business fundamentals look? Do top analysts think Beone Medicines is a good buy? Why has ONC's stock price moved recently? (Hint: Our stock market research tools can help you figure out if ONC is a good stock to buy).
- Place your ONC purchase: Decide if you will purchase ONC shares at the current market price or use a limit order to buy ONC shares at a given price.
- Monitor your ONC position: Create a watchlist to monitor your investment in Beone Medicines stock.
Step 1: Choose where to buy Beone Medicines stock
You will need an online brokerage account in order to access the NASDAQ market and buy ONC shares.
Our preferred brokerage: eToro
In our opinion, eToro is the best brokerage. eToro gives you:
- You can invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
- Access to global markets: From Technology to Financial Services, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top stock exchanges.
- Social investing: eToro has a community with more than 20 million users globally. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by opening an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've chosen the best brokerage, the next step is to fill out some personal details so you can invest in ONC stock today.
How to Start a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal data to open a new brokerage account.
- Submit your application by pressing the "Create Account" button. Get started with eToro today
Step 3: Put funds into your investment account
Now that you've filled out your info on mobile trading apps, you need to deposit funds:
Check out the tutorial below to see the process of depositing money into your new brokerage account.
Step 4: Evaluate Beone Medicines stock
Once you have selected the best place to buy Beone Medicines stock, it's very important to research their stock before you buy, so you actually wrap your head around the risk as well as the opportunity.
Beone Medicines shares quick numbers
ONC Due Diligence Score
WallStreetZen was built to help everyday investors do more accurate fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on ONC's stock page.
Is ONC stock properly valued?
Analysts use many financial metrics, analyses, models, and charts to gauge ONC's fair value.
Using relative valuations measures:
- ONC may be overvalued based on its P/E ratio of 1,378.45x, relative to Biotechnology industry P/E ratio of 27.68x
- ONC could be overvalued based on its P/B ratio of 7.02x, relative to Biotechnology industry P/B ratio of 4.59x
You can do additional valuation analysis on ONC's stock here.
ONC Financial Health
Positive Health Checks:
- There are more short-term assets than short-term liabilities on the ONC balance sheet.
- ONC earnings of $475.09M is not enough to cover its interest payments.
- There are more short-term assets than long-term liabilities on the ONC balance sheet.
- ONC profit margin has gone up from -16.9% to 5.4% in the past year.
- ONC's operating cash flow of $1.13B allows it to safely service it's debt of $2.00B.
Negative Health Checks:
- ONC has a relatively high debt to equity ratio of 0.88.
- Total ONC debt is higher than 5 years ago, relative to shareholder equity.
Do analysts think it's a good time to buy ONC stock
Out of 9 Equities analysts who track ONC, the consensus analyst rating on Beone Medicines is a Strong Buy
Please note that analyst ratings are not recommendations, nor are they financial advice.
Latest ONC Analyst Forecasts
Yigal Nochomovitz, a top 14% analyst from Citigroup maintains ONC with a strong buy rating and raises their ONC price target from $399.00 to $405.00, on Nov 10, 2025.
Citigroup's Yigal Nochomovitz raised their price target on Beone Medicines (NASDAQ: ONC) by 1.5% from $399 to $405 on 2025/11/11. The analyst maintained their Strong Buy rating on the stock.
BeOne Medicines reported its Q3 2025 earnings.
The quarter's impressive performance was highlighted by Brukinsa's consensus-beating performance, Nochomovitz told readers.
Earnings Report
For Q3 2025, Beone Medicines reported:
- EPS of $2.65, which beat the Zacks Consensus Estimate $0.72 and, by 463%, Q3 2024’s $0.49.
- Revenue of $1.41B, which beat the Zacks Consensus Estimate of $1.34 and, by 41% Q3 2024’s $1B.
For FY 2025, management guided:
- Revenue of $5.1B to $5.3B.
Co-Founder, Chairman, & CEO John V. Oyler commented: “These strong financial results reinforce our position as a global oncology leader with exceptional topline growth and a strong balance sheet.
“BRUKINSA is now the global revenue leader in the BTKi class, supported by long-term efficacy and safety data and a growing body of evidence reinforcing its scientific hypothesis of sustained BTK inhibition.
“Our late-stage hematology portfolio continues to advance with sonrotoclax, a potentially best-in-class BCL2 inhibitor that has demonstrated impressive clinical results, and our BTK CDAC BGB-16673, further strengthening our leadership in B cell malignancies, including CLL.
“With one of the most promising oncology pipelines in the industry, we are poised to deliver multiple data and regulatory milestones that will drive long-term value.”
Reni J. Benjamin, a bottom 10% analyst from Citizens maintains ONC with a buy rating and raises their ONC price target from $348.00 to $396.00, on Nov 7, 2025.
Sean Laaman, a top 25% analyst from Morgan Stanley maintains ONC with a strong buy rating and raises their ONC price target from $350.00 to $383.00, on Oct 20, 2025.
Jessica Fye, a top 5% analyst from JP Morgan maintains ONC with a strong buy rating and raises their ONC price target from $345.00 to $385.00, on Oct 8, 2025.
You can dive deeper into what analysts are forecasting on the Beone Medicines stock forecast page.
ONC Technicals
Is ONC Making Money?
Last year, ONC revenue was $5.34B. Over the last five year, ONC's revenue has increased by 76.85% per year. This was faster than the Biotechnology industry average of 28.26%.
Dive into ONC's earnings and revenue performance here.
Latest Insiders Trades at ONC
In the last 12 months, insiders at ONC have bought more shares than they have sold.
Chan Henry Lee, SVP General Counsel of ONC, was the latest ONC insider to buy. They bought $21,391.70 worth of ONC shares on Mar 11, 2026.
Research more about who owns ONC shares here.
Can I rely on ONC as an income stream?
No, Beone Medicines doesn't provide an income stream by paying out dividends.
What do other traders have to say about ONC?
One of the major reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other community members have to say.
Step 5: Place your ONC purchase
You have two primary types of orders:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are generally fine for most investors. - Limit order: A limit order is an order to buy or sell a stock at a specific price (or better).
If you want to be certain you're buying or selling at a given price limit, place a limit order.
Hit the Open Trade button and your broker will place your order.
If you need more info about buying stocks on eToro, watch the helpful video below:
Step 6: Monitor your ONC position
Now that you own some shares in ONC, you'll want to keep up with your investment.
Put ONC on a watchlist to get the latest updates about your ONC stock.
ONC Feed
How to Buy Stock in Beone Medicines
To reiterate, here are the 6 steps to buy stock in Beone Medicines:
- Choose where to buy Beone Medicines stock
- Create your brokerage account
- Put funds into your investment account
- Evaluate Beone Medicines stock
- Place your ONC purchase
- Monitor your ONC position
If you need a brokerage account, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to monitor your investment in Beone Medicines, add ONC to your watchlist by clicking the button below.
Other Content You Might Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.